



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/681,788	10/08/2003	Habib Zaghouni	07316.0002.CPUS01	6701
22930 7590 08/24/2007 HOWREY LLP C/O IP DOCKETING DEPARTMENT 2941 FAIRVIEW PARK DR, SUITE 200 FALLS CHURCH, VA 22042-2924			EXAMINER EWOLDT, GERALD R	
			ART UNIT 1644	PAPER NUMBER
			MAIL DATE 08/24/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/681,788	Applicant(s) ZAGHOUBANI ET AL.	
	Examiner G. R. Ewoldt, Ph.D.	Art Unit 1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11/14/06, 11/22/06, 2/9/07, and 6/19/07.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13 and 15-26 is/are pending in the application.
- 4a) Of the above claim(s) 8-12, 20 and 21 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7, 13, 15-19 and 22-26 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1644

DETAILED ACTION

1. Applicant's election without traverse of Group II, a method employing a GAD peptide or fragment, filed 11/14/06, is acknowledged.

Claims 8-12, 20, and 21 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to non-elected inventions.

Claims 1-7, 13, 15-19, and 22-26 are under examination.

2. The Abstract and the Title are objected to because they do not adequately describe the claimed invention. Applicant is advised that an Abstract and Title commensurate in scope with the invention of the instant claims are required. See MPEP 608.01(b).

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 23 and 24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, specifically, "in within" would more properly be "within".

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 1-7, 13, 15-19, and 22-24 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

Art Unit: 1644

Under *Vas-Cath, Inc. v. Mahurkar*, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed.

There is insufficient written description to show that Applicant was in possession of a "protein fragment or peptide derived from GAD", except for GAD65 peptides 524-543 and 206-220.

The claims encompass the use of a genus of any peptides or "derivatives" of GAD. Thus, the claims encompass peptides comprising additions, deletions, mutations, etc., none of which are described in the specification. It is clear that the genus is large, indeed it might be essentially unlimited. Accordingly, one of skill in the art would conclude that the specification fails to disclose a representative number of species, or a common structure and function among the peptides of protein fragments, to describe the claimed genus. See *Eli Lilly*, 119 F.3d 1559, 43 USPQ2d 1398.

7. Claims 1-7, 13, 15-19, and 22-26 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Specifically, the specification provides insufficient evidence that the claimed method could effectively function as a method for suspending, preventing or delaying the onset of type I diabetes (IDDM).

The specification disclosure is insufficient to enable one skilled in the art to practice the invention as claimed without an undue amount of experimentation. Undue experimentation must be considered in light of factors including: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill in the art, the level of predictability of the art, the amount of direction provided by the inventor, the existence of working examples, and the quantity of experimentation needed to make or use the invention, see *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

Art Unit: 1644

In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) states, "The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art." "The "amount of guidance or direction" refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling" (MPEP 2164.03). The MPEP further states that physiological activity can be considered inherently unpredictable. With these teachings in mind, an enabling disclosure, commensurate in scope with the breadth of the claimed invention, is required.

While the mechanism of action for the method of the instant claims is not disclosed, it appears to require inducing tolerance to GAD and altered GAD "derived" peptides. Tolerance-inducing peptide immunotherapy is well known in the immunological arts. In some cases significant results have been demonstrated in in-bred small animal models. However, said results have not been repeated in human trials. See for example, *Marketletter* (9/13/99) which teaches the complete failure in human trials of two peptides designed for tolerance induction. Both Myloral (for multiple sclerosis, MS) and Colloral (for rheumatoid arthritis, RA) provided successful results in rodent models (EAE and collagen induced arthritis, respectively).

As set forth above, the references demonstrate that even unsubstituted peptides (peptides that are not APLs) that work in *in vivo* small animal disease models cannot be expected to work in humans. Regarding the even more unpredictable APLs, Anderton (2001), teaches that,

"This unpredictability [of APLs] led us to argue against the use of antagonist or immune deviating APL in human autoimmune disorders" (page 370).
Indeed, the reference goes on to teach that APL administration to humans can be dangerous and that in at least one case a human trial was suspended due to adverse reactions in a significant number of patients.

Art Unit: 1644

Other investigators have discussed additional problems in establishing human tolerance. See, for example, Dong et al. (1999),

"Despite the fact that it has been relatively easy to induce true tolerance in small experimental animals, translating these studies into larger animals and humans has been much more difficult to achieve. Some of the hurdles that may explain this dilemma are summarized in Table 3. *Even if we have the ideal strategy to use in humans, the lack of reliable predictable assays for rejection or tolerance still does not allow us to know if a patient is truly tolerant so that immunosuppressive agents may be withdrawn*",
emphasis added.

A review of the instant specification shows just a single long example wherein a T cell response to a single insulin B chain peptide (amino acids 9-23) is inhibited in the experimental NOD mouse model of IDDM. First note that the instant claims are drawn to the use of GAD, not insulin, for the suspending, preventing or delaying the onset of IDDM. Thus, the specification offers no data in support of the claimed method. Interestingly, the specification discloses, that even regarding the use of an insulin peptide for the suspending, preventing or delaying the onset of IDDM, *the method of the instant claims cannot function as claimed*, emphasis added. For example, at page 28 of the specification, it is disclosed that, "Soluble Ig-INS β displayed dose dependent delay of diabetes when given at either stage [pre or post IAA conversion]. However, aggregated Ig-INS β , which induced IL-10 and TGF β -producing T cells, thus involving sustained endogenous IL-10, was protective against diabetes when given before development of insulinitis *but had no effect in predisposed mice positive for IAA*", emphasis added. Further, Examples 7 and 9 teach that neither soluble nor aggregated Ig-INS β can actually prevent IDDM, but rather can only delay onset under specific conditions.

Additionally, Applicant's subsequent work demonstrates that the method of the instant claims would not be expected to function as claimed. See for example Legge et al. (1998). Therein the authors teach that APLs function as, "T cell antagonists, partial agonists, or super agonists" (page 106). The authors go on to teach that PLP-LR stimulated PLP-1 specific T cells (paragraph spanning page 109 and 110), i.e., the T cells that would be pathogenic in an MS patient. Given that no experiments have been performed employing GAD peptides and

Art Unit: 1644

derivatives thereof, it is just as likely that the method of the instant claims would actually exacerbate disease as treat or prevent it.

A set forth in *Rasmusson v. SmithKline Beecham Corp.*, 75 USPQ2d 1297, 1302 (CAFC 2005), enablement cannot be established unless one skilled in the art "would accept without question" an Applicant's statements regarding an invention, particularly in the absence of evidence regarding the effect of a claimed invention. Specifically:

"As we have explained, we have required a greater measure of proof, and for good reason. If mere plausibility were the test for enablement under section 112, applicants could obtain patent rights to "inventions" consisting of little more than respectable guesses as to the likelihood of their success. When one of the guesses later proved true, the "inventor" would be rewarded the spoils instead of the party who demonstrated that the method actually worked. That scenario is not consistent with the statutory requirement that the inventor enable an invention rather than merely proposing an unproved hypothesis."

Thus, in view of the quantity of experimentation necessary, the lack of sufficient guidance in the specification, the lack of sufficient working examples, i.e., the specification discloses no data regarding the treatment or prevention of IDDM employing GAD peptides, and the unpredictability of the art, it would take undue trials and errors to practice the claimed invention.

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

9. Claims 1-7, 13, 15-19, and 22-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 98/30706 in view of Kaufman et al. (1992).

WO 98/30706 teaches the treatment of autoimmune disorders, including IDDM, (see particularly pages 10 and 19) employing an

Art Unit: 1644

engineered fusion protein, e.g., a humanized IgG_{2b} chimeric protein wherein an autoantigen peptide is inserted into the D segment of a CDR3 loop (see particularly Figure 1, page 13, and Example II).

The method differs from the claimed invention only in that it does not teach the use of GAD65 as the autoantigen employed for the treatment of IDDM.

Kaufman et al. teach that GAD65 (which would comprise amino acid residues 206-220 and 524-543), along with insulin, is a well-known IDDM autoantigen (see particularly page 283, column 2).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to perform the method of WO 98/30706 for the treatment of IDDM employing the autoantigen of Kaufman et al. One of ordinary skill in the art at the time the invention was made would have been motivated to select GAD65 as the autoantigen for use in the claimed method given the teachings of Kaufman et al. that GAD65 was one of the few known IDDM autoantigens at the time of the invention. Regarding the timing of administration of the Ig-fusion protein set forth in claims such as 3, 16, 17, etc., said timing would comprise only routine optimization which would fall well within the purview of one of skill in the art at the time of the invention.

10. Claims 1-7, 13, 15-19, and 22-26 are rejected under 35 U.S.C. § 112, first paragraph, as the specification does not contain a written description of the claimed invention, in that the disclosure does not reasonably convey to one skilled in the relevant art that the inventor(s) had possession of the claimed invention at the time the application was filed. This is a new matter rejection.

The specification and the claims as originally filed do not provide support for the invention as now claimed, specifically:

A) the "at least one CDR" and the "at least one protein fragment or peptide derived from GAD" employed in the claimed method (Claim 1 and others).

Applicant indicates that support for the new amendments can be found at pages 22 and 46 of the specification, but support for the limitations as set forth above has not been found.

Art Unit: 1644

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12. Claims 1-7, 13, 15-19, and 22-26 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 62-65 of U.S. Patent Application No. 10/510,411. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the '411 application recite a method comprising treating IDDM with a GAD construct such as would be encompassed by that recited in Claim 1.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

13. Claims 1-7, 13, 15-19, and 22-26 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-7 and 13-16 of U.S. Patent Application No. 11/290,070. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the '070 application recite a method comprising treating IDDM with a GAD construct such as would be encompassed by that recited in Claim 1.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Art Unit: 1644

14. Claims 1-7, 13, 15-19, and 22-26 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-7 and 13-16 of U.S. Patent Application No. 11/425,084. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the '084 application recite a method comprising treating IDDM with a GAD construct such as would be encompassed by that recited in Claim 1.


This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

15. No claim is allowed.

16. Applicant is reminded of the duty to disclose **ALL** information material to patentability, as set forth in 37 CFR 1.56, including **ALL** applications, including those subsequently filed, claiming the same invention as that of the instant application.

17. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

18. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197



G.R. Ewoldt, Ph.D.
Primary Examiner
Technology Center 1600